The Additive Clinical Value of F-18-FDG PET/CT in Defining the Recurrence of Disease in Patients With Differentiated Thyroid Cancer Who Have Isolated Increased Antithyroglobulin Antibody Levels


ÖZKAN E., SOYDAL Ç., ARAZ M., Aras G., İBİŞ E.

CLINICAL NUCLEAR MEDICINE, vol.37, no.8, pp.755-758, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 8
  • Publication Date: 2012
  • Doi Number: 10.1097/rlu.0b013e31825ae77b
  • Journal Name: CLINICAL NUCLEAR MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.755-758
  • Keywords: differentiated thyroid cancers, antithyroglobulin antibody, F-18-FDG PET/CT, SERUM THYROGLOBULIN MEASUREMENT, FOLLOW-UP, CARCINOMA, AUTOANTIBODIES, PREVALENCE, SCAN
  • Ankara University Affiliated: Yes

Abstract

Aim: The aim of this study was to investigate the additive clinical value of F-18-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer (DTC) who have isolated increased antithyroglobulin antibody (TgAb) levels with undetectable thyroglobulin (Tg) levels and negative I-131 whole-body scintigraphy (wbs).